After years of slow progress, and with very little supporting clinical data, Abbvie pledges to push into a major Garp inhibition programme.
Bispecifics targeting Tigit and CTLA4 head into phase 3 development, as the developer follows Bristol out of IL-12.
The group continues its niche-targeting strategy with abelacimab’s latest pivotal trial.
Astra’s stealthy move into cell therapy has yielded a truly novel cancer target, and the company could be in clinical trials soon.
Imjudo’s clinical development period was almost the longest of any drug in recent memory. Here are some others.